<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956278</url>
  </required_header>
  <id_info>
    <org_study_id>14-14550</org_study_id>
    <secondary_id>R01DK103729</secondary_id>
    <nct_id>NCT02956278</nct_id>
  </id_info>
  <brief_title>The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics</brief_title>
  <official_title>The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Open Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will undergo a placebo and allopurinol phase to better understand the effects of the
      reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxypurinol Renal Clearance</measure>
    <time_frame>24 hours (Urine collected 0-4 hrs,4-8 hrs,8-10 hrs,10-24 hrs post-dose)</time_frame>
    <description>Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change Uric Acid</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum percent change in uric acid after a single dose of allopurinol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxypurinol AUC</measure>
    <time_frame>24 hours (Collections at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24 hours post-dose)</time_frame>
    <description>Area under the concentration time curve from 0-24 hours following a single dose of allopurinol (i.e. Day 1 of both protocols)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Chronic Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>BCRP Q141K CC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCRP Q141K CA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCRP Q141K AA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>BCRP Q141K AA</arm_group_label>
    <arm_group_label>BCRP Q141K CA</arm_group_label>
    <arm_group_label>BCRP Q141K CC</arm_group_label>
    <other_name>Zyloprim</other_name>
    <other_name>Aloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose placebo pill</description>
    <arm_group_label>BCRP Q141K AA</arm_group_label>
    <arm_group_label>BCRP Q141K CA</arm_group_label>
    <arm_group_label>BCRP Q141K CC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self-identified as Asian/European ancestry

          -  generally healthy with approved lab values for CBC,HFP,RFP, and uric acid

          -  Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major
             allele of rs2231142 will be recruited

        Exclusion Criteria:

          -  vascular disease

          -  renal impairment

          -  medications/supplements that affect uric acid levels

          -  pregnant or lactating women

          -  prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801
             allele

          -  risk of urinary or gastric retention or narrow-angle glaucoma

          -  impaired hepatic function

          -  evidence of anemia

          -  evidence or diagnosis of congestive heart failure

          -  smokers

          -  subjects with a mutation other than rs2231142 in the ABCG2 genotype

          -  subjects taking hormonal contraceptives or other hormonal medications

          -  evidence of recreational drug use as determined by questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Giacomini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Open Medicine Institute</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <results_first_submitted>May 27, 2019</results_first_submitted>
  <results_first_submitted_qc>June 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Single Dose Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02956278/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Multiple Dose Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02956278/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>As the intent of the protocol was to characterize the effect of the genetic variant, data were collected and analyzed per genotype variant regardless of number of doses received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BCRP Q141K CC</title>
          <description>Participants that are homozygous reference for BCRP Q141K receive one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours.</description>
        </group>
        <group group_id="P2">
          <title>BCRP Q141K CA</title>
          <description>Participants that are heterozygous for the BCRP Q141K allele receive one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours.</description>
        </group>
        <group group_id="P3">
          <title>BCRP Q141K AA</title>
          <description>Participants homozygous for the BCRP Q141K allele receive one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were analyzed based on their BCRP Q141K genotype no matter which protocol (single or multiple dose) they participated in.</population>
      <group_list>
        <group group_id="B1">
          <title>BCRP Q141K CC Genotype</title>
          <description>All subjects that completed the protocol with the reference BCRP Q141K genotype (CC alleles)</description>
        </group>
        <group group_id="B2">
          <title>BCRP Q141K CA Genotype</title>
          <description>All subjects that completed the protocol with the heterozygous BCRP Q141K genotype (CA alleles)</description>
        </group>
        <group group_id="B3">
          <title>BCRP Q141K AA Genotype</title>
          <description>All subjects that completed the protocol with the homozygous BCRP Q141K genotype (AA alleles)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="5.7"/>
                    <measurement group_id="B2" value="29.0" spread="7.2"/>
                    <measurement group_id="B3" value="27.3" spread="6.5"/>
                    <measurement group_id="B4" value="27.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oxypurinol Renal Clearance</title>
        <description>Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours</description>
        <time_frame>24 hours (Urine collected 0-4 hrs,4-8 hrs,8-10 hrs,10-24 hrs post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCRP Q141K CC Genotype</title>
            <description>All subjects that completed the protocol with the reference BCRP Q141K genotype (CC alleles)</description>
          </group>
          <group group_id="O2">
            <title>BCRP Q141K CA Genotype</title>
            <description>All subjects that completed the protocol with the heterozygous BCRP Q141K genotype (CA alleles)</description>
          </group>
          <group group_id="O3">
            <title>BCRP Q141K AA Genotype</title>
            <description>All subjects that completed the protocol with the homozygous BCRP Q141K genotype (AA alleles)</description>
          </group>
        </group_list>
        <measure>
          <title>Oxypurinol Renal Clearance</title>
          <description>Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.5"/>
                    <measurement group_id="O3" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change Uric Acid</title>
        <description>Maximum percent change in uric acid after a single dose of allopurinol</description>
        <time_frame>24 hours</time_frame>
        <population>Baseline and minimum SUA level after a single dose of allopurinol (i.e. Day 1) were used for the calculation (baseline-minimum)/baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>BCRP Q141K CC Genotype</title>
            <description>All subjects that completed the protocol with the reference BCRP Q141K genotype (CC alleles)</description>
          </group>
          <group group_id="O2">
            <title>BCRP Q141K CA Genotype</title>
            <description>All subjects that completed the protocol with the heterozygous BCRP Q141K genotype (CA alleles)</description>
          </group>
          <group group_id="O3">
            <title>BCRP Q141K AA Genotype</title>
            <description>All subjects that completed the protocol with the homozygous BCRP Q141K genotype (AA alleles)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change Uric Acid</title>
          <description>Maximum percent change in uric acid after a single dose of allopurinol</description>
          <population>Baseline and minimum SUA level after a single dose of allopurinol (i.e. Day 1) were used for the calculation (baseline-minimum)/baseline)</population>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="5.9"/>
                    <measurement group_id="O2" value="23.8" spread="7.0"/>
                    <measurement group_id="O3" value="21.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxypurinol AUC</title>
        <description>Area under the concentration time curve from 0-24 hours following a single dose of allopurinol (i.e. Day 1 of both protocols)</description>
        <time_frame>24 hours (Collections at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24 hours post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCRP Q141K CC Genotype</title>
            <description>All subjects that completed the protocol with the reference BCRP Q141K genotype (CC alleles)</description>
          </group>
          <group group_id="O2">
            <title>BCRP Q141K CA Genotype</title>
            <description>All subjects that completed the protocol with the heterozygous BCRP Q141K genotype (CA alleles)</description>
          </group>
          <group group_id="O3">
            <title>BCRP Q141K AA Genotype</title>
            <description>All subjects that completed the protocol with the homozygous BCRP Q141K genotype (AA alleles)</description>
          </group>
        </group_list>
        <measure>
          <title>Oxypurinol AUC</title>
          <description>Area under the concentration time curve from 0-24 hours following a single dose of allopurinol (i.e. Day 1 of both protocols)</description>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="25.1"/>
                    <measurement group_id="O2" value="99.1" spread="30.1"/>
                    <measurement group_id="O3" value="108.5" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the course of the protocol and up to 72 hours following the final dose of allopurinol</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCRP Q141K CC</title>
          <description>Participants homozygous reference for BCRP Q141K receive one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours.</description>
        </group>
        <group group_id="E2">
          <title>BCRP Q141K CA</title>
          <description>Participants heterozygous for BCRP Q141Kr eceive one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours.</description>
        </group>
        <group group_id="E3">
          <title>BCRP Q141K AA</title>
          <description>Participants homozygous for BCRP Q141Kr eceive one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathy Giacomini, PhD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-514-4363</phone>
      <email>kathy.giacomini@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

